ArticleTranslational lung cancer research2024
Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Association of body mass index and serum markers with immune-related adverse events in lung cancer patients receiving immune checkpoint inhibitors.Journal of thoracic disease · 2026Article
- Impact of immune-related toxicity on survival and treatment response in non-small cell lung cancer patients.BMC pulmonary medicine · 2026Observational
- Association Between Chronic Obstructive Pulmonary Disease and Survival in Patients with Lung Cancer: A Nationwide Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Development of immune-related adverse events is associated with improved survival outcomes in cancer patients receiving immune checkpoint inhibitors.Frontiers in immunology · 2026Article
- A Latent profile and network intervention analysis of psychosomatic symptoms in lung cancer immunotherapy patients.PloS one · 2026Article
- Immune-related adverse events and clinical outcomes in patients with solid tumors treated with adebrelimab: a real-world exploratory study.Frontiers in oncology · 2026Article
- Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy.Internal medicine (Tokyo, Japan) · 2026Review
- Impact of immune-related adverse events on treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors.Frontiers in immunology · 2026Article
- Checkpoint Inhibitor Pneumonitis: Key Insights for Pulmonologists.Medicina (Kaunas, Lithuania) · 2025Review
- Current status of management of immune-related adverse events and practical needs for oncologist education.Cancer biology & medicine · 2025Review
- Assessing the prognosis of metastatic or recurrent non-small cell lung cancer in the era of modern systemic therapies: a multivariable analysis of 343 patients treated in Poland.Translational lung cancer research · 2025Article
- The Impact of Immune-Related Adverse Event Severity on Prognosis in Elderly Patients With Nonsmall-Cell Lung Cancer in First-Line Immune Checkpoint Inhibitor Treatment.Thoracic cancer · 2025Article
- Lung squamous cell carcinoma with metastases in the left atrium and left ventricle responds to treatment with immunotherapy: A case report.Oncology letters · 2025Article
- Case report: pembrolizumab-induced acute type 1 diabetes mellitus and diabetic ketoacidosis in a perioperative esophageal squamous cell carcinoma patient.AME case reports · 2025Article
- Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study).Frontiers in immunology · 2025Article
- Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers.Cancer control : journal of the Moffitt Cancer CenterArticle
- Pneumonitis in Older Patients With Non-squamous Non-small Cell Lung Cancer Treated With Pembrolizumab and Pemetrexed.In vivo (Athens, Greece)Article
- Consecutive Uncontrolled Gastrointestinal Immune-Related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) work by activating the immune system, a mechanism that may also cause immune-related adverse events (irAEs). This study seeks to investigate on how different irAEs impact prognosis of advanced lung cancer (LC) patients and identify useful approaches to manage irAEs. Methods: A thorough literature search of PubMed, Embase, the Cochrane Library and manual searches up to January 2024 were undertaken. Treatment outcomes including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) were obtained. Meta-analysis was conducted using R software (version 4.3.1). Results: There were 106 studies with 41,050 advanced or recurrent LC patients included. The occurrence of irAEs was correlated with better PFS [hazard ratio (HR) =0.54; 95% confidence interval (CI): 0.49-0.59], OS (HR =0.57; 0.51-0.63), ORR [risk ratio (RR) =2.03; 95% CI: 1.81-2.28] and DCR (RR =1.55; 95% CI: 1.40-1.72) and remained significant after adjusting programmed death-ligand 1 (PD-L1) level. IrAEs affecting skin (OS: HR =0.45; 95% CI: 0.38-0.53) and endocrine system (OS: HR =0.51; 95% CI: 0.41-0.62), of mild severity (OS: HR =0.52; 95% CI: 0.35-0.79), arising in multiple sites (OS: HR =0.47; 95% CI: 0.38-0.59), induced by monotherapy (OS: HR =0.58; 95% CI: 0.52-0.65), with a delayed onset (cutoff: 3 months; OS: HR =0.37; 95% CI: 0.19-0.71) were identified as positive prognostic markers. In contrast, though pulmonary irAEs were found to be corelated with enhanced treatment response (ORR: RR =1.75; 95% CI: 1.37-2.25), they may harm survival, especially those with grade ≥3 (OS: HR =2.40; 95% CI: 1.39-4.14). Treatment resumption tended to improve PFS but might not reduce the risk of death compared to permanent discontinuation. Conclusions: IrAEs suggest better treatment outcomes generally, yet severe pneumonia could increase mortality risk. Close supervision and appropriate handling protocols are warranted to weigh treatment benefit against risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.